Business Context and Reporting Period
Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: November 2, 2011
Reporting Period: Third quarter ended September 30, 2011
Context: The filing serves to announce third-quarter 2011 results via an attached Investor News release (Exhibit 99.1). The Company utilizes non-GAAP measures, specifically EBITDA and free cash flow, to supplement GAAP results.
Key Financial Metrics
The provided text is a cover letter for the Form 6-K and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached Exhibit 99.1 (Investor News), which is referenced but not included in the input text.
- Revenue/Profit: Not provided in text.
- Cash Flow: Not provided in text.
- Debt/Liquidity: Not provided in text.
- Non-GAAP Measures: The Company reports EBITDA (operating income excluding interest, taxes, depreciation, and amortization) and free cash flow.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only states that the attached Investor News contains the consolidated financial results and reconciliations necessary to compare current performance to prior periods.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures are provided to enhance the user's understanding of current financial performance and future prospects. They emphasize that these measures provide consistency and comparability with prior periods.
Regulatory Note: The Company explicitly states that non-GAAP measures should not be used as a substitute for or considered superior to GAAP financial measures.
Risks/Contingencies: No specific risks or contingencies are detailed in the cover letter text. The filing notes that the attached Exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific revenue and profit figures in the attached Exhibit 99.1 (Investor News).
- Review the reconciliation of non-GAAP EBITDA and free cash flow to GAAP measures as required by Regulation G.
- Confirm the impact of the third-quarter results on the Company's full-year outlook.
- Check for any specific segment performance details (e.g., Dialysis, Renal Products) not summarized in this cover letter.